Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Revance Therapeutics (NASDAQ: RVNC) announced its participation in the 34th Annual Piper Sandler Healthcare Conference from November 29 to December 1, 2022, in New York City. CEO Mark J. Foley will present on November 29 at 10:00 AM ET. The live audio webcast will be accessible on the company’s Investor Relations webpage and will remain available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic products and is known for offerings like DAXXIFY™ and the RHA® Collection. The company also collaborates with Viatris to develop a biosimilar to BOTOX®.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 34^th Annual Piper Sandler Healthcare Conference, taking place November 29-December 1, 2022, in New York City. Chief Executive Officer, Mark J. Foley, is scheduled to present on Tuesday, November 29, at 10:00AM ET.

Interested parties can access the live audio webcast for this conference from the Events page of the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY™ in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com or connect with us on LinkedIn.

“Revance” and the Revance logo and OPUL are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005262/en/

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Source: Revance Therapeutics, Inc.

FAQ

When is Revance Therapeutics presenting at the Piper Sandler Healthcare Conference?

Revance Therapeutics will present on November 29, 2022, at 10:00 AM ET.

Where is the 34th Annual Piper Sandler Healthcare Conference being held?

The conference is taking place in New York City.

How can I access the Revance Therapeutics conference presentation?

The presentation can be accessed via a live audio webcast on the Investor Relations section of Revance's website.

What products does Revance Therapeutics focus on?

Revance specializes in innovative aesthetic and therapeutic offerings, including DAXXIFY™ and the RHA® Collection.

What is Revance's collaboration with Viatris about?

Revance is partnering with Viatris to develop a biosimilar to BOTOX®.